Stockreport

Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma...

Moderna, Inc.  (MRNA) 
Last moderna, inc. earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: marinabio.com/investor-relations
PDF CAMBRIDGE, MA / ACCESS Newswire / April 17, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from a Phase 1/2 study of mRNA-4359, a [Read more]